One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.